With the recent published results of DESKTOP III, do you intend to change your practice of performing secondary cytoreductive surgery for recurrent, platinum-sensitive ovarian cancer?  

Since Dr. @Robert L. Coleman's 2018 long awaited ASCO presentation of the results of GOG-0213, I have taken pause before considering a patient for secondary cytoreductive surgery (CRS). Over the last decade, I have also performed less primary CRS and more neoadjuvant chemotherapy. The changes in my ...